NuVasive

NuVasive, Inc. engages in the development, manufacture, sale, and provision of procedural solutions for spine surgery. It offers a comprehensive portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NuVasive is a medical device company that creates minimally invasive surgical products and procedurally integrated spine solutions. Its minimally invasive, procedurally integrated surgical solutions are intended to produce repeatable and clinically proven results.

SAN DIEGO , Nov. 17, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, held a virtual event yesterday showcasing the Company's latest innovation across its market-leading 360 portfolios. "Changing the lives of patients around the globe is the foundation of NuVasive—and we fulfill our purpose through a continued commitment to being the industry's innovation leader," said Chris Barry, chief executive officer at NuVasive.

NuVasive Showcases Latest Innovation in Virtual Global Event

SAN DIEGO , Nov. 16, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Executive Officer Chris Barry will participate in the Piper Sandler 34th Annual Healthcare Conference in New York on Wednesday, November 30, 2022 at 12:30 p.m. ET. A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com.

NuVasive to Participate in Piper Sandler 34th Annual Healthcare Conference

SAN DIEGO , Nov. 14, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Cervical Spine Research Society (CSRS) as a diamond sponsor and will attend the CSRS 50th Annual Meeting held November 16 to 19 in San Diego. "The recent launch of our leading posterior cervical fusion solution, Reline Cervical, and our annual meeting sponsorship of a preeminent cervical society, CSRS, underscores our shared belief in further advancing cervical technology," said Chris Barry, chief executive officer at NuVasive.

NuVasive to Sponsor and Participate at the Cervical Spine Research Society 50th Annual Meeting

NuVasive, Inc. (NASDAQ:NUVA ) Q3 2022 Earnings Conference Call November 9, 2022 4:30 PM ET Company Participants Juliet Cunningham - Vice President-Investor Relations Chris Barry - Chief Executive Officer Matt Harbaugh - Chief Financial Officer Conference Call Participants Matt Miksic - Barclays Joshua Jennings - Cowen Vikramjeet Chopra - Wells Fargo Joanne Wuensch - Citibank Samuel Brodovsky - Truist Shagun Singh - RBC David Saxon - Needham & Company Jeffrey Johnson - Baird Matthew Taylor - Jefferies Allen Gong - JPMorgan Matthew O'Brien - Piper Sandler Matthew Blackman - Stifel Operator Good day, ladies and gentlemen, and welcome to the NuVasive Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to introduce your host for today's call, Miss.

NuVasive, Inc. (NUVA) Q3 2022 - Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of 1.89% and 0.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Surpasses Q3 Earnings Estimates

– Net sales grew 9.0% as reported, 12.9% on a constant currency basis – – C360 portfolio delivers record quarter in cervical net sales – – Company updates full-year 2022 guidance – SAN DIEGO , Nov. 9, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Net sales were $295.3 million, a 9.0% increase as reported and a 12.9% increase on a constant currency basis, compared to the prior year period; GAAP operating margin of 7.4%; Non-GAAP operating margin of 13.6%; and GAAP diluted loss per share of ($0.04); Non-GAAP diluted earnings per share of $0.54.

NuVasive Announces Third Quarter 2022 Financial Results

SAN DIEGO , Nov. 7, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of the NuVasive Tube System (NTS) and Excavation Micro, a new minimally invasive surgery (MIS) system that provides comprehensive solutions for both TLIF and decompression. These additions expand the Company's access and instrumentation technology offerings within the NuVasive P360 portfolio.

NuVasive Launches Tube System and Excavation Micro for Posterior Spine Surgery

NuVasive (NUVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NuVasive (NUVA) Reports Next Week: Wall Street Expects Earnings Growth

The share price declined by ~46% since the beginning of the coronavirus pandemic crisis in 2020. Revenues returned to the growth path thanks to high R&D expenses and acquisitions.

NuVasive: Prepared To Endure Current Headwinds

SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close. NuVasive will hold a conference call on Wednesday, November 9, 2022, at 4:30 p.m.

NuVasive Announces Conference Call and Webcast of Third Quarter 2022 Results

SAN DIEGO , Oct. 17, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with EUROSPINE as a gold sponsor and will attend EUROSPINE 2022 held October 19 to 21 in Milan. "Our support of EUROSPINE reflects our belief in partnering with the most influential societies, study groups and congresses around the globe to advance better spine care and change the lives of more patients," said Chris Barry, chief executive officer at NuVasive.

NuVasive to Sponsor and Participate at EUROSPINE 2022

SAN DIEGO , Sept. 29, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, has announced the planned agenda for the Company's Investor Day 2022, which will be hosted at the NuVasive West Coast Experience Center in San Diego on Thursday, October 6, 2022, with presentations beginning at 9:00 a.m.

NuVasive Announces Agenda for Investor Day 2022

The cervical solution marks the completion of the NuVasive Reline fixation portfolio for complex deformity from occiput to sacrum SAN DIEGO , Sept. 28, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the commercial launch of Reline® Cervical, a new fixation system for posterior cervical fusion (PCF), in targeted regions.

NuVasive Launches Reline Cervical for Posterior Cervical Fusion as Part of the C360 Portfolio

SAN DIEGO , Sept. 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will continue its partnership with the Society for Minimally Invasive Spine Surgery (SMISS) as a sponsor and will attend the SMISS Annual Forum '22 held September 29 to October 1, 2022 in Las Vegas.

NuVasive to Sponsor and Participate at Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum '22

NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock?

NuVasive (NUVA) Down 16.2% Since Last Earnings Report: Can It Rebound?

SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the resignation of Massimo Calafiore, executive vice president and chief commercial officer, effective August 31, 2022, to become the chief executive officer of a privately-held, orthopedics technology company. Upon Mr. Calafiore's resignation, his responsibilities will be reallocated among current members of management while the Company aligns its commercial structure to its long-term strategy.

NuVasive Announces Departure of Chief Commercial Officer

NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.

NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat

NuVasive, Inc. (NASDAQ:NUVA ) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Juliet Cunningham – Vice President-Investor Relations Chris Barry – Chief Executive Officer Matt Harbaugh – Chief Financial Officer Conference Call Participants Josh Jennings – Cowen Vik Chopra – Wells Fargo Joanne Wuensch – Citi Shagun Singh – RBC Capital Markets Allen Gong – JPMorgan Rich Newitter – Truist Securities Drew Ranieri – Morgan Stanley Jason Wittes – Loop Capital Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the NuVasive Second Quarter 2022 Earnings Conference Call. I would now like to introduce your host for today's call, Ms.

NuVasive, Inc. (NUVA) CEO Chris Barry on Q2 2022 Results - Earnings Call Transcript

NuVasive (NUVA) delivered earnings and revenue surprises of -14.55% and 1.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Lags Q2 Earnings Estimates

–Strong year-over-year net sales growth, driven by new product introductions– –Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%– –Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022 – SAN DIEGO , Aug. 3, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Net sales were $310.5 million, a 5.3% increase as reported and a 7.8% increase on a constant currency basis, compared to the prior year period; GAAP operating margin of 10.7%; Non-GAAP operating margin of 13.0%; and GAAP diluted loss per share of ($0.02); Non-GAAP diluted earnings per share of $0.47.

NuVasive Announces Second Quarter 2022 Financial Results

SAN DIEGO, July 28, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that Chief Financial Officer Matt Harbaugh will participate in the Canaccord Genuity 42nd Annual Growth Conference in Boston on Thursday, August 11, 2022 at 1:30 p.m. ET. A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at www.nuvasive.com.

NuVasive to Participate in Canaccord Genuity 42nd Annual Growth Conference

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: NuVasive (NUVA) Q2 Earnings Expected to Decline

Spine surgeons validated clinical and economic benefits of an entirely synthetic solution in lateral lumbar fusions SAN DIEGO , July 26, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the results of the study "Can a bioactive interbody device reduce the cost burden of achieving lateral lumbar fusion?" in the Journal of Neurosurgery: Spine.

Clinical Study Validates NuVasive Porous Interbody Implant and Synthetic Bone Graft Substitute as Cost-effective Solution for Lateral Lumbar Interbody Fusions

SAN DIEGO , July 18, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter results on Wednesday, August 3, 2022, after the close of the market. NuVasive will hold a conference call on Wednesday, August 3, 2022, at 4:30 p.m.

NuVasive Announces Conference Call and Webcast of Second Quarter 2022 Results

ResMed

NUVA vs. RMD: Which Stock Is the Better Value Option?

News for NuVasive Stock (NUVA)